Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2019

Summarized financial information related to this collaboration is as follows:



Years Ended December 31	2019		2018
Alliance revenue	$	404	$	149

Cost of sales⁽¹⁾	206		39
Selling, general and administrative	80		13
Research and development ⁽²⁾	189		1,489

December 31	2019		2018
Receivables from Eisai included in Other current assets	$	150	$	71
Payables to Eisai included in Accrued and other current liabilities ⁽³⁾	700		375
Payables to Eisai included in Other Noncurrent Liabilities ⁽³⁾	525		543

⁽¹⁾Represents amortization of capitalized milestone payments.

⁽²⁾Amount for 2018 includes $1.4 billion related to the upfront payment and option payments.

⁽³⁾Includes accrued milestone and future option payments.

Summarized financial information related to this collaboration is as follows:



Years Ended December 31	2019		2018		2017
Net product sales recorded by Merck	$	215	$	190	$	149
Merck’s profit share from sales in Bayer’s marketing territories	204		139		151
Total sales	419		329		300

Cost of sales ⁽¹⁾	113		216		99
Selling, general and administrative	41		35		27
Research and development	126		127		101

December 31	2019		2018
Receivables from Bayer included in Other current assets	$	49	$	32
Payables to Bayer included in Other Noncurrent Liabilities ⁽²⁾	375		375

⁽¹⁾ Includes amortization of intangible assets.

⁽²⁾Represents accrued milestone payment.

Summarized financial information related to this collaboration is as follows:



Years Ended December 31	2019		2018		2017
Alliance revenue	$	444	$	187	$	20

Cost of sales ⁽¹⁾	148		93		4
Selling, general and administrative	138		48		1
Research and development ⁽²⁾	168		152		2,419

December 31	2019		2018
Receivables from AstraZeneca included in Other current assets	$	128	$	52
Payables to AstraZeneca included in Accrued and other current liabilities⁽³⁾	577		405
Payables to AstraZeneca included Other Noncurrent Liabilities ⁽³⁾	—		250

⁽¹⁾ Represents amortization of capitalized milestone payments.

⁽²⁾ Amount for 2017 includes $2.35 billion related to the upfront payment and license option payments.

⁽³⁾ Includes accrued milestone payments.